Volume 18, Issue 3, Pages (March 2003)

Slides:



Advertisements
Similar presentations
Induction of Graft-versus-Leukemia (GVL) Effect without Graft-versus-Host Disease (GVHD) by Pretransplant Donor Treatment with Immunomodulators  Shoshana.
Advertisements

Cheng-Ming Sun, Edith Deriaud, Claude Leclerc, Richard Lo-Man  Immunity 
Host-Derived CD8+ Dendritic Cells Protect Against Acute Graft-versus-Host Disease after Experimental Allogeneic Bone Marrow Transplantation  Michael Weber,
William H. D. Hallett, Weiqing Jing, William R. Drobyski, Bryon D
High-Risk Acute Lymphoblastic Leukemia Cells with bcr-abl and Ink4a/Arf Mutations Retain Susceptibility to Alloreactive T Cells  Faith M. Young, Andrew.
Induction of anergic allergen-specific suppressor T cells using tolerogenic dendritic cells derived from children with allergies to house dust mites 
Influence of Donor Microbiota on the Severity of Experimental Graft-versus-Host- Disease  Isao Tawara, Chen Liu, Hiroya Tamaki, Tomomi Toubai, Yaping Sun,
Stromal-Derived Factor-1α and Interleukin-7 Treatment Improves Homeostatic Proliferation of Naïve CD4+ T Cells after Allogeneic Stem Cell Transplantation 
Extracorporeal Photopheresis Attenuates Murine Graft-versus-Host Disease via Bone Marrow–Derived Interleukin-10 and Preserves Responses to Dendritic Cell.
Identification of Stem Cell Transcriptional Programs Normally Expressed in Embryonic and Neural Stem Cells in Alloreactive CD8+ T Cells Mediating Graft-versus-Host.
Juyang Kim, Wongyoung Kim, Hyun J. Kim, Sohye Park, Hyun-A
Identification of CD3+CD4−CD8− T Cells as Potential Regulatory Cells in an Experimental Murine Model of Graft-Versus-Host Skin Disease (GVHD)  Fumi Miyagawa,
Differential Effects of Gut-Homing Molecules CC Chemokine Receptor 9 and Integrin-β7 during Acute Graft-versus-Host Disease of the Liver  Alina Schreder,
Induction of Immunity to Neuroblastoma Early after Syngeneic Hematopoietic Stem Cell Transplantation Using a Novel Mouse Tumor Vaccine  Weiqing Jing,
by Yoshinobu Maeda, Pavan Reddy, Kathleen P
Ping Zhang, Jieying Wu, Divino Deoliveira, Nelson J. Chao, Benny J
Apoptotic Donor Leukocytes Limit Mixed-Chimerism Induced by CD40-CD154 Blockade in Allogeneic Bone Marrow Transplantation  Jian-ming Li, John Gorechlad,
Human NK cell development in NOD/SCID mice receiving grafts of cord blood CD34+ cells by Christian P. Kalberer, Uwe Siegler, and Aleksandra Wodnar-Filipowicz.
Volume 136, Issue 3, Pages (March 2009)
Ex Vivo Rapamycin Generates Th1/Tc1 or Th2/Tc2 Effector T Cells With Enhanced In Vivo Function and Differential Sensitivity to Post-transplant Rapamycin.
LBH589 Enhances T Cell Activation In Vivo and Accelerates Graft-versus-Host Disease in Mice  Dapeng Wang, Cristina Iclozan, Chen Liu, Changqing Xia, Claudio.
The histone methyltransferase Ezh2 is a crucial epigenetic regulator of allogeneic T-cell responses mediating graft-versus-host disease by Shan He, Fang.
Volume 25, Issue 11, Pages (November 2017)
PreImplantation Factor Reduces Graft-versus-Host Disease by Regulating Immune Response and Lowering Oxidative Stress (Murine Model)  Yehudith Azar, Reut.
Induction of Graft-versus-Leukemia (GVL) Effect without Graft-versus-Host Disease (GVHD) by Pretransplant Donor Treatment with Immunomodulators  Shoshana.
Graft-Versus-Leukemia Effect and Graft-Versus-Host Disease Can Be Differentiated by Cytotoxic Mechanisms in a Murine Model of Allogeneic Bone Marrow Transplantation.
Donor T Cells Administered Over HLA Class II Barriers Mediate Antitumor Immunity without Broad Off-Target Toxicity in a NOD/Scid Mouse Model of Acute.
Evelyn C. Nieves, Tomomi Toubai, Daniel C
Pharmacologic Expansion of Donor-Derived, Naturally Occurring CD4+Foxp3+ Regulatory T Cells Reduces Acute Graft-versus-Host Disease Lethality Without.
Volume 19, Issue 6, Pages (December 2003)
The Triterpenoid CDDO-Me Delays Murine Acute Graft-versus-Host Disease with the Preservation of Graft-versus-Tumor Effects after Allogeneic Bone Marrow.
Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease by Tangsheng Yi, Dongchang Zhao, Chia-Lei.
Volume 18, Issue 5, Pages (May 2003)
Ananda W Goldrath, Michael J Bevan  Immunity 
Volume 35, Issue 6, Pages (December 2011)
The Pentostatin Plus Cyclophosphamide Nonmyeloablative Regimen Induces Durable Host T Cell Functional Deficits and Prevents Murine Marrow Allograft Rejection 
Essential Role of Interleukin-12/23p40 in the Development of Graft-versus-Host Disease in Mice  Yongxia Wu, David Bastian, Steven Schutt, Hung Nguyen,
NKT Cells Inhibit the Onset of Diabetes by Impairing the Development of Pathogenic T Cells Specific for Pancreatic β Cells  Lucie Beaudoin, Véronique.
Volume 31, Issue 2, Pages (August 2009)
Volume 31, Issue 1, Pages (July 2009)
T helper17 Cells Are Sufficient But Not Necessary to Induce Acute Graft-Versus-Host Disease  Cristina Iclozan, Yu Yu, Chen Liu, Yaming Liang, Tangsheng.
Volume 132, Issue 1, Pages (January 2007)
The Triterpenoid CDDO-Me Delays Murine Acute Graft-versus-Host Disease with the Preservation of Graft-versus-Tumor Effects after Allogeneic Bone Marrow.
Host Basophils Are Dispensable for Induction of Donor T Helper 2 Cell Differentiation and Severity of Experimental Graft-versus-Host Disease  Isao Tawara,
Therapeutic Action of Ghrelin in a Mouse Model of Colitis
A Radio-Resistant Perforin-Expressing Lymphoid Population Controls Allogeneic T Cell Engraftment, Activation, and Onset of Graft-versus-Host Disease in.
Dynamic Change and Impact of Myeloid-Derived Suppressor Cells in Allogeneic Bone Marrow Transplantation in Mice  Dapeng Wang, Yu Yu, Kelley Haarberg,
Volume 44, Issue 3, Pages (March 2016)
Amotosalen-treated donor T cells have polyclonal antigen-specific long-term function without graft-versus-host disease after allogeneic bone marrow transplantation 
Volume 28, Issue 6, Pages (June 2008)
Tracking ex vivo-expanded CD4+CD25+ and CD8+CD25+ regulatory T cells after infusion to prevent donor lymphocyte infusion-induced lethal acute graft-versus-host.
Volume 29, Issue 6, Pages (December 2008)
Volume 33, Issue 4, Pages (October 2010)
Volume 19, Issue 4, Pages (October 2003)
Volume 19, Issue 3, Pages (September 2003)
CD25 expression distinguishes functionally distinct alloreactive CD4+ CD134+ (OX40+) T-cell subsets in acute graft-versus-host disease  Philip R Streeter,
Volume 135, Issue 3, Pages (September 2008)
Volume 38, Issue 3, Pages (March 2013)
Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation  Jian-Ming Li, Edmund K.
Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD4+25+ T cells to allow an effective graft-versus-leukemia response 
Brile Chung, Eric Dudl, Akira Toyama, Lora Barsky, Kenneth I. Weinberg 
Early Vaccination with Tumor Lysate-Pulsed Dendritic Cells after Allogeneic Bone Marrow Transplantation Has Antitumor Effects  Jeffrey S. Moyer, Gabriel.
Raimon Duran-Struuck, Isao Tawara, Kathi Lowler, Shawn G
Targeting ST2 Alleviates Graft-Versus-Host Disease Mortality and Maintains Graft- Versus-Leukemia  Jilu Zhang, PhD, Benjamin Ulrich, Abdulraouf Ramadan,
Induction of Lethal Graft-versus-Host Disease by Anti-CD137 Monoclonal Antibody in Mice Prone to Chronic Graft-versus-Host Disease  Wonyoung Kim, Juyang.
Roles of CD28, CTLA4, and Inducible Costimulator in Acute Graft-versus-Host Disease in Mice  Jun Li, Kenrick Semple, Woong-Kyung Suh, Chen Liu, Fangping.
Volume 13, Issue 11, Pages (December 2015)
Volume 37, Issue 2, Pages (August 2012)
Volume 10, Issue 5, Pages (February 2015)
A Key Role of Leptin in the Control of Regulatory T Cell Proliferation
Presentation transcript:

Volume 18, Issue 3, Pages 367-379 (March 2003) Regulatory Dendritic Cells Protect Mice from Murine Acute Graft-versus-Host Disease and Leukemia Relapse  Katsuaki Sato, Naohide Yamashita, Naomi Yamashita, Masanori Baba, Takami Matsuyama  Immunity  Volume 18, Issue 3, Pages 367-379 (March 2003) DOI: 10.1016/S1074-7613(03)00055-4 Copyright © 2003 Cell Press Terms and Conditions

Figure 1 rDCs Regulate the Function of T Cells The panels that are listed in the legend but do not appear here are posted as Supplemental Data. (A) Cells were stained with the stated mAbs, and cell surface expression was analyzed by flow cytometry. Data are represented by a dot plot. (B) CD4+ T cells (H-2b) were cultured with mDCs or rDCs (H-2d) at various T cell:DC ratios, and the proliferative response was measured. (C and D) I-Kb+CD4+ T cells or I-Kd+CD4+ T cells obtained from the transplanted recipients (H-2d) (C) or (H-2q) (D) were cultured with mDCs (H-2d) (C) or (H-2q) (D) in the presence or absence of mDCs or rDCs obtained from the indicated strains at various T cell:DC ratios, and the proliferative response was measured. Primed CD4+ T cells (H-2b) plus mDCs (H-2d) (C) or primed CD4+ T cells (H-2d) plus mDCs (H-2q) (D) versus any other group, P < 0.01. (E and F) I-Kb+CD8+ T cells or I-Kd+CD8+ T cells obtained from the transplanted recipients (H-2d) (E) or (H-2b) (F) were cultured with medium alone (none) or the indicated types of DCs at a T cell/DC ratio of 10:1 and were subjected to CTL assay against the targeted cells obtained from various strains. CD8+ T cells alone versus any other group, P < 0.01. (G and H) CD4+ T cells (H-2b) (G) or (H-2d) (H) were cultured with or without the indicated types of DCs (H-2d) (G) or (H-2q) (H) at a T cell/DC ratio of 10:1 in a first coculture. In another experiment, CD4+ T cells obtained from a first coculture were then cultured with medium alone (none) or mDCs obtained from various strains at a T cell/DC ratio of 10:1 in the presence or absence of IL-2 in a second coculture, and the proliferative response was measured. Primed CD4+ T cells (H-2b) plus mDCs (G) or primed CD4+ T cells (H-2d) plus mDCs (H) versus any other group, P < 0.01. Five replicate experiments with similar results were pooled. Immunity 2003 18, 367-379DOI: (10.1016/S1074-7613(03)00055-4) Copyright © 2003 Cell Press Terms and Conditions

Figure 2 rDCs Protected the Recipients of Allogeneic BMS from the Lethality Caused by Acute GVHD (A and B) Recipients (H-2d) of BM cells or BMS (H-2b) were injected with or without the indicated types of DCs 2 days after transplantation. (C) Recipients (H-2b) of BMS (H-2q) were injected with or without the indicated types of DCs 2 days after transplantation. (D) Recipients (H-2d) of BMS (H-2b) were injected with or without various doses of rDCs (H-2d) on the indicated days after transplantation. (E and F) Recipients (H-2d) of BMS (H-2b) injected with rDCs (H-2d) were treated with the indicated Abs (E) or injected with the indicated types of CD4+CD25+ T cells (H-2b) (F) after transplantation as described in Experimental Procedures. Untreated recipients of allogeneic BMS versus any other group, P < 0.01. Two replicate experiments with similar results were pooled. Immunity 2003 18, 367-379DOI: (10.1016/S1074-7613(03)00055-4) Copyright © 2003 Cell Press Terms and Conditions

Figure 3 rDCs Impair Allogeneic Ag-Specific Responses of CD4+ T Cells and CD8+ T Cells in Transplanted Mice Recipients (H-2d) of BMS (H-2b) were injected with or without mDCs or rDCs (H-2d), and spleen mononuclear cells and sera were obtained from each group 5 days after transplantation. (A) Cells were stained with the stated mAbs, and cell surface expression was analyzed by flow cytometry. Data are expressed as percent positive cells. (B) I-Kb+CD4+ T cells obtained from spleen mononuclear cells were cultured with medium alone (none) or mDCs (H-2d or H-2q) in the presence or absence of IL-2 at a T cell/DC ratio of 10:1, and the proliferative response was measured. (C) I-Kb+CD8+ T cells obtained from spleen mononuclear cells were subjected to CTL assay against P815 cells or EL4 cells. (D) Concentrations of IFN-γ, TNF-α, and IL-12p40 in sera were evaluated by ELISA. Untreated recipients of allogeneic BMS versus any other group, P < 0.01. (E) Recipients (H-2d) of BMS (H-2b) were injected with CFSE-labeled rDCs (H-2d) 2 days after transplantation, and CFSE-labeled rDCs in spleen mononuclear cells were determined at the indicated days after injection by flow cytometry. Five replicate experiments with similar results were pooled. Immunity 2003 18, 367-379DOI: (10.1016/S1074-7613(03)00055-4) Copyright © 2003 Cell Press Terms and Conditions

Figure 4 Characterization of Donor-Derived CD4+CD25+ T Cells in Transplanted Mice The panels that are listed in the legend but do not appear here are posted as Supplemental Data. Allogeneic transplantation was performed as described in Figure 3, and I-Kb+CD4+ T cells were obtained from spleen mononuclear cells in each group. (A and B) I-Kb+CD4+ T cells were assayed for phenotype (A) and cytokine profile (B) by flow cytometry. Data are expressed as percent positive cells. CD4+ T cells obtained from normal mice versus any other group, P < 0.01. (C) CD4+CD25+ T cells isolated from normal mice (H-2b) or I-Kb+CD4+CD25+ T cells isolated from I-Kb+CD4+ T cells in each group of recipients were assayed for phenotype by flow cytometry. Data are represented by a dot plot. (D) Unprimed CD4+CD25+ T cells (H-2b) or I-Kb+CD4+ CD25+ T cells isolated from rDC-treated recipients on the indicated days after transplantation were assayed for CD152 expression by flow cytometry. Data are expressed as percent positive cells. Unprimed CD4+CD25+ T cells versus any other group, P < 0.01. (E) CD4+ T cells (H-2b), unprimed CD4+CD25+ T cells (H-2b), and/or I-Kb+CD4+CD25+CD152+ T cells were cultured with or without mDCs or rDCs (H-2d or H-2q) at a T cell/DC ratio of 10:1, and the proliferative response was measured. (F) CD4+ T cells (H-2b) were cultured with mDCs (H-2d) at a T cell/DC ratio of 10:1 in the presence or absence of the different numbers of unprimed CD4+CD25+ T cells or I-Kb+CD4+CD25+CD152+ T cells isolated from rDC-treated recipients on day 5 after transplantation, and the proliferative response was measured. (G) CD4+ T cells (H-2b) were cultured with mDCs (H-2d) in the presence or absence of unprimed CD4+CD25+ T cells or I-Kb+CD4+CD25+ T cells isolated from rDC-treated recipients on the indicated days after transplantation at a T cell/CD25+T cell/DC ratio of 10:1:1, and the proliferative response was measured. (H) CD4+ T cells (H-2b) were cultured with or without mDCs (H-2d) in the presence or absence of I-Kb+CD4+CD25+ CD154+ T cells, I-Kb+CD4+CD25+CD152+ T cells, or IL-2 at a T cell/CD25+T cell/DC ratio of 10:10:1. For Transwell experiments, I-Kb+CD4+CD25+CD152+ T cells plus mDCs (H-2d) were either added directly to the coculture of CD4+ T cells (H-2b) with mDCs (H-2d) or were separated in 24-well plates. Following depletion of mDCs, T cells were transferred to 96-well plates to measure the proliferative response. CD4+ T cells plus mDCs (E, G, H) or CD4+ T cells, unprimed CD4+CD25+ T cells plus mDCs (G) versus any other group, P < 0.01. Five replicate experiments with similar results were pooled. Immunity 2003 18, 367-379DOI: (10.1016/S1074-7613(03)00055-4) Copyright © 2003 Cell Press Terms and Conditions

Figure 5 Involvement of cAMP and p27kip1 in an Induction of Allogeneic Ag-Specific Tolerant CD4+ T Cells by rDCs (A, C, and D) CD4+ T cells (H-2b) were obtained from the coculture of CD4+ T cells (H-2b) with the indicated types of DCs (H-2d) or I-Kb+CD4+ CD25+CD152+ Tr cells as described in Figure 4 at a T cell/DC ratio of 10:1 or at a T cell/CD25+ T cell ratio of 1:1. (B and E) Allogeneic transplantation was performed as described in Figure 3, and I-Kb+CD4+ T cells obtained from spleen mononuclear cells in each group were then cultured with mDCs (H-2d or H-2q) at a T cell/DC ratio of 10:1. Following these procedures, CD4+ T cells were isolated from the coculture. (A and B) The concentration of intracellular cAMP was measured. (C, D, and E) The expression of p27kip1 was analyzed by immunoblot. Five replicate experiments with similar results were pooled. Immunity 2003 18, 367-379DOI: (10.1016/S1074-7613(03)00055-4) Copyright © 2003 Cell Press Terms and Conditions

Figure 6 GVL Effect in rDC-Treated Leukemia-Bearing Recipients of Allogeneic BMS Leukemia (H-2d)-bearing recipients (H-2d) received BM (H-2b), BMS (H-2b), and/or rDCs (H-2d) as described in Experimental Procedures. (A and B) Recipients were monitored for survival (A) and body weight (B). (C) Liver and spleen were obtained from representative recipients at the time of death or 60 days after transplantation to determine their weight. Recipients that received TBI plus the inoculation with P815 cells versus any other group, P < 0.01. Two replicate experiments with similar results were pooled. Immunity 2003 18, 367-379DOI: (10.1016/S1074-7613(03)00055-4) Copyright © 2003 Cell Press Terms and Conditions